Michael Lidsky

Dr. Michael Lidsky received his medical degree from Georgetown University School of Medicine in 2009 and completed his surgery residency at Duke University in 2016. Upon completion of residency, he completed subspecialty training in complex general surgical oncology and hepatopancreatobiliary surgery at Memorial Sloan Kettering Cancer Center in 2018. Dr. Lidsky then returned to Duke in 2018 as faculty within the Department of Surgery and the Division of Surgical Oncology at Duke University. His clinical practice focuses on the surgical management of cancerous and pre-cancerous conditions of the liver, biliary tree, and pancreas. Dr. Lidsky also implemented and leads the Hepatic Artery Infusion (HAI) team at Duke, a rapidly growing program to deliver high-dose chemotherapy directly to the liver for patients with advanced primary and secondary liver cancers, including metastases from colorectal cancer and unresectable intrahepatic cholangiocarcinoma. He also co-founded and co-leads the HAI Consortium Research Network (HCRN), a collaborative of over 200 surgeons and medical oncologists representing nearly 80 HAI centers in the United States and internationally. Dr Lidsky is also the national study chair and site PI for several NIH-funded randomized trials. In addition to Dr. Lidsky’s clinical practice, his basic science and translational research explores functional genomic and molecular mechanisms of tumorigenesis and chemoresistance in primary liver cancer. Specifically, he uses pre-clinical models of cholangiocarcinoma to recapitulate critical events in these tumors, so as to identify mechanisms driving tumor growth, metastasis, and resistance to chemotherapy, as well as inherent tumor-specific dependencies that can be therapeutically exploited.